Heart Has Intrinsic Ketogenic Capacity that Mediates NAD+ Therapy in HFpEF

By sjmartinez • April 11, 2025

Koay YC, McIntosh B, Ng YH, Cao Y, Wang X, Han Y, Tomita S, Bai AY, Hunter B, Misra A, Loughrey CM, Bannon PG, Lal S, Lusis AJ, Kaye DM, Larance M, O'Sullivan JF. Heart Has Intrinsic Ketogenic Capacity that Mediates NAD⁺ Therapy in HFpEF. Circ Res. 2025 Apr 11. doi: 10.1161/CIRCRESAHA.124.325550. Epub ahead of print. PMID: 40211954.

Tags: Cardiology/Epi, heart failure, ketone bodies, myocardium, oxygen consumption, Publications, stroke volume

The Spatial Transcriptional Activity of Hepatic TCF7L2 Regulates Zonated Metabolic Pathways that Contribute to Liver Fibrosis

Ayala I, Hebbale SK, Mononen J, Brearley-Sholto MC, Shannon CE, Valdez I, Fourcaudot M, Bakewell TM, Zagorska A, Romero G, Asmis M, Musa FA, Sily[...]

Pathways and Molecular Mechanisms Governing LDL Receptor Regulation

Schmidt HM, Jarrett KE, de Aguiar Vallim TQ, Tarling EJ. Pathways and Molecular Mechanisms Governing LDL Receptor Regulation. Circ Res. 2025 Apr 11;136(8):902-919. doi: 10.1161/CIRCRESAHA.124.323578.[...]

Atorvastatin versus rosuvastatin in acute myocardial infarction with elevated liver enzymes: a target trial emulation study

Chen X, Liu H, Li L, A G, Sun P, Tan DS, Chan MY, Foo RS, Fonarow GC, Yang Q, Zhou X. Atorvastatin versus rosuvastatin[...]